ASLAN Pharmaceuticals Limited (ASLN)
July 26, 2024 - ASLAN Pharmaceuticals Limited was delisted.
0.6000
-0.1000 (-14.27%)
Inactive · Last trade price on Jul 18, 2024

Company Description

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients.

The company’s clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor α1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases.

It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan.

The company was founded in 2010 and is headquartered in Singapore.

ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals logo
CountrySingapore
Founded2010
IPO DateMay 4, 2018
IndustryBiotechnology
SectorHealthcare
Employees35
CEODr. Carl Alan Jason Morton Firth EMBA, Ph.D.

Contact Details

Address:
83 Clemenceau Avenue, #12-03 Ue Square
Singapore, U0 239920
Phone65 6222 4235
Websiteaslanpharma.com

Stock Details

Ticker SymbolASLN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001722926
CUSIP Number04522R101
ISIN NumberUS04522R2004
SIC Code2834

Key Executives

NamePosition
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.Founder, Chief Executive Officer and Executive Director
Kiran Kumar AsarpotaChief Operating Officer and Head of Finance
Ben GoodgerGeneral Counsel
Stephen DoyleChief Business Officer
Dr. Alexandre Kaoukhov M.D.Chief Medical Officer
Charlie HsuInvestor Relations Director
Chi-Chin WangIR and Corporate Development Director

Latest SEC Filings

DateTypeTitle
Jul 17, 20246-KReport of foreign issuer
Jul 15, 20246-KReport of foreign issuer
Jun 21, 2024EFFECTNotice of Effectiveness
Jun 14, 2024UPLOADFiling
Jun 14, 20246-KReport of foreign issuer
Jun 14, 2024F-6 POSPost-effective amendments for immediately effective filing
Jun 12, 2024F-3Filing
May 31, 20246-KReport of foreign issuer
May 9, 20246-KReport of foreign issuer
May 7, 20246-KReport of foreign issuer